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INTRODUCTION: Antiviral therapy (AVT) for chronic hepatitis B (CHB) can prevent liver disease progression. Because of
its stringent reimbursement criteria, significant numbers of patients with untreated minimally active
(UMA)-CHB exist, although they are still subject to disease progression. We thus performed a cost-
effectiveness analysis to assess the rationale for AVT for UMA-CHB.
METHODS: We compared cost and effectiveness (quality-adjusted life years, QALYs) in virtual UMA-CHB cohorts of
10,000 50-year-olds receiving AVT (scenario 1) vs no treatment (scenario 2) for 10 years. A Markov
model, including 7 health states of CHB-related disease progression, was used. Values for transition
probabilities and costs were mostly obtained from recent South Korean data.
RESULTS: The simulation of AVT vs no treatment predicted $2,201 incremental costs and 0.175 incremental
QALYs per patient for 10 years, with an incremental cost-effectiveness ratio (ICER) of $12,607/QALY,
suggesting cost-effectiveness of AVT. In sum, if 10,000 patients received AVT, 720 incident
hepatocellular carcinoma and 465 CHB-relatedmore deaths could be averted in 10 years relative to no
treatment. When the simulated analysis period was extended to 20 years, AVT was also highly cost-
effective with an ICER of $2,036/QALY. Although hepatocellular carcinoma–related mortality was a
major factor influencing ICER, its fluctuation can be accepted within willingness to pay of $33,000 in
South Korea. According to probabilistic sensitivity analysis with the threshold of willingness to pay, the
probability of AVT cost-effectiveness was 83.3%.
DISCUSSION: Long-term AVT for patients with UMA-CHB may contribute positively toward individual clinical benefit
and national health care budget.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A493
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection remains a substantial
global public health issue, affectingmore than 250million people,
despite a universal vaccination program (1). As a persistently high
level of HBV replication in patients with chronic hepatitis B
(CHB) is associated with an increased risk of cirrhosis and/or
hepatocellular carcinoma (HCC) development (2,3), replication-
suppressing antiviral therapy (AVT) using oral nucleoside/nu-
cleotide analogues (NUCs) is the mainstay of current practice to
prevent live disease progression (4). To date, entecavir and
tenofovir disoproxil fumarate (TDF), which have a high genetic
barrier to resistance (4,5) and similarly excellent degree of clinical
efficacy in terms of virological, biochemical, serological, and
histological responses, have been favored antivirals (4–6). Nev-
ertheless, reimbursement for oral NUCs remains limited inmany
countries. It is officially permitted when the following criteria are
fulfilled in the absence of HCC or cirrhosis: (i) elevated serum
HBV-DNA level ($20,000 IU/mL for hepatitis B e antigen-
positive CHB or$2,000 IU/mL for hepatitis B e antigen-negative
CHB) and (ii) serum alanine aminotransferase$23 upper limit
of normal (4–8). Accordingly, significant numbers of patients
have minimally active CHB (9,10), whereby serum HBV-DNA
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levels are persistently .2,000 IU/mL, a threshold that is closely
associated with an increased risk of liver disease progression to
HCC and/or cirrhosis (2,3). Nevertheless, the aforementioned
criteria for NUC therapy may not be fulfilled during follow-up;
therefore, patients remain untreated, resulting in persistently
higher risk of disease progression throughout their lifetimes.
Clinical outcomes of patientswithprogression to advanced liver
disease of HCC and/or cirrhosis are unsatisfactory. The 5-year
overall survival rate of patients with HCC is less than 50%, and the
1-year mortality rate from cirrhotic complications among those
with decompensated cirrhosis exceeds 10%–21% (11–13). To date,
cost-effectiveness analyses of AVT using oral NUCs for this sub-
group beyond the definite reimbursement guidelines are lacking.
Achieving a statistically significant benefit from AVT with regard
to preserving liver function, reducing HCC risk, and ultimately
improving overall survival generally requires long-term treatment.
In this regard, prolonged use of oral NUCswould increase the total
socioeconomic burden. Here, we aimed to evaluate whether long-
term AVT with oral NUCs is a cost-effective approach in patients
with untreated minimally active (UMA)-CHB.
METHODS
Overview of the cost-effectiveness model
In this study, we performed a cost-effectiveness analysis using a
Markov model to compare the following 2 scenarios for patients
withUMA-CHBwhodid notmeet the reimbursement criteria for
NUC therapy (entecavir or TDF) by the National Health In-
surance Service (NHIS) in South Korea: patients withUMA-CHB
undergoing NUC therapy (scenario 1) vs those not receiving
NUC therapy due to ineligibility including the current practice
environment (scenario 2). The current reimbursement criteria of
the NHIS in South Korea are described in Supplementary Table 1
(see Supplementary Digital Content, http://links.lww.com/CTG/
A493). The model constituted 7 comprehensive clinical condi-
tions that may develop in patients with UMA-CHB until the end
of life; these health states are represented as bubbles in Figure 1 to
reflect the entire clinical history of the disease: (i) UMA-CHB;
(ii) CHB with virological response (CHB-VR), which takes into
account the transition from UMA-CHB to CHB-VR either
spontaneously or from NUC therapy; (iii) compensated cirrhosis
(CC); (iv) decompensated cirrhosis (DCC); (v) HCC; (vi) liver
transplantation (LT); and (vii) death (Figure 1) (14).
A hypothetical cohort of patients aged 50 years (n 5 10,000)
was created. The analysis began when the cohort of patients
reached UMA-CHB—the first state of the disease. Each cycle pe-
riod was 1 year, and the hypothetical cohort of patients was dis-
tributed to each state according to transitionprobabilities at the end
of one cycle. An analytic period of 10 years was used in the base-
case analysis, which was conducted from the perspective of the
health care system. A 5% discount rate was used for the analysis.
This studywas approved byYonsei Institutional ReviewBoard
(IRB No. 7001988-201907-HR-635-01E). The need for patient
consent was waived due to the use of untraceable and deidentified
secondary claims data.
Transition probabilities
The transition probabilities of each cycle were crucial factors for
estimating the number of the cohort of patients distributed across
the 7 defined states. These transition probabilities are indicated by
arrows in Figure 1. Transition probabilities were obtained from
previous literature by selecting studies that involved patient
groups similar to those used in this study. Considering the typical
steep variations in outcomes for patients with hepatitis B for the
first year after initiating NUC therapy and flattened variations in
subsequent outcomes, the transition probabilities of the first cycle
differed from those of subsequent cycles within the 10-year pe-
riod. Thus, for scenario 1, inwhich patients withUMA-CHBwere
undergoing NUC therapy, the transition probability fromUMA-
CHB to CHB-VR was estimated at 0.80 for the first year and 0.53
after the first year (the cumulative VR rate reached 99.4% in year
5) (15). For predicting progression to CC state from UMA-CHB
state in both scenarios 1 and 2, the probability was obtained from
the cumulative incidence of liver cirrhosis, whereby the cumu-
lative incidence of liver cirrhosis over 5 years was estimated at
10.3% for the control group (16), and then calculated at an in-
cidence rate of 0.022. The transition probability fromUMA-CHB
to HCC was computed at 0.011 in both scenarios based on the
study by Lee et al. (9,10), in which the cumulative risk of HCC
development was estimated at 9.8% in 9 years. For scenario 2, in
which patients with UMA-CHB did not undergo NUC therapy,
the transition probability of the VR, which indicates the proba-
bility of natural conversion to the VR state from the UMA-CHB
state, was calculated at 0.025, based on the study byChen et al. (3),
in which the level of HBV-DNA was decreased below 10,000
copies/mL in 402 of 1,619 patients with$10,000 copies/mL over
a mean follow-up of 11.4 years).
The same probabilities were applied to both scenarios re-
garding transitions from CHB-VR state. The transition proba-
bility from CHB-VR state to CC state was calculated as 0.007
(cumulative incidence at 5 years was 3.36%) and as 0.002 forHCC
state (cumulative incidence at 9 years was 2.2%) (10,16). The
transition probability from CC to DCC state was calculated as
0.011 (17). The incidence rate of transition to HCC fromCC state
was calculated from 4 teaching hospitals in South Korea and the
value used was as 0.043 (the weighted cumulative risk of HCC
development at 5 years; 21.6% in 499 entecavir patients and 16.8%
Figure 1.Markovmodel structure for cost-effectiveness analysis of the use
of NUC therapy in the UMA-CHB group. CHB, chronic hepatitis B; NUC,
nucleos(t)ide analogue; UMA, untreated minimally active; VR, virological
response.





Table 1. Transition probabilities
Annual transition probability Value
SourceHealth states Scenario 1 (NUC therapy) Scenario 2 (no treatment)
UMA-CHB
At the first year
To UMA-CHB 0.167 0.942 Calculationa
To CHB-VR 0.800 0.025 Cho et al. (15) for scenario 1; Chen et al. (3) for
scenario 2
After year 1
To UMA-CHB 0.436 0.942 Calculationa
To CHB-VR 0.531 0.025 Cho et al. (15) for scenario 1; Chen et al. (3) for
scenario 2
Any year
To CC 0.022 0.022 Chang et al. (16)
To HCC 0.011 0.011 Lee et al. (10)
Both scenarios
CHB-VR
To VR 0.991 Calculationa
To CC 0.007 Chang et al. (16)
To HCC 0.002 Lee et al. (10)
CC
To CC 0.946 Calculationa
To DCC 0.011 Kim et al. (17)
To HCC 0.043 Kim et al. (18)
DCC
To DCC 0.598 Calculationa
To HCC 0.078 Jang et al. (19)
To LT 0.211 Jang et al. (19)
To death 0.114 Kim et al. (20)
HCC
To HCC 0.690 Calculationa
To LT 0.016 Kim et al. (21)
To Death 0.294 Kim et al. (21)
LT
To LT 0.769 Calculationa
To death 0.231 Data from KONOS (22)
Death
To death 1.000 —
Cumulative incidence of adverse eventsb Scenario 1 Scenario 2
CKD 0.02 (after 3 yr) — Lim et al. (23)
Osteopenia 0.025 (during 4–8 yr period) — Marcellin et al. (24)
Osteoporosis 0.025 (during 4–8 yr period) — Marcellin et al. (24)
Ratio of NUC therapy (entecavir/TDF) 0.92 (50.48/0.52) — Data from HIRA (HIRA-NPS-2016-0164)
(27,28)
CC, compensated cirrhosis; CHB-VR, chronic hepatitis B with virological response; CKD, chronic kidney disease; DCC, decompensated cirrhosis; HCC, hepatocellular
carcinoma; HIRA, health insurance review and assessment service; LT, liver transplantation; NUC, nucleos(t)ide analogue; TDF, tenofovir disoproxil fumarate; UMA-CHB,
untreated minimally active chronic hepatitis B.
aIf health status remained the same state after 1 cycle, transition probability was calculated by 1 2 all other transition probabilities.
bTransition probabilities of adverse events were applied only in the use of TDF.
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in 411 TDF patients) (18). The transition probability was 0.078
for DCC to HCC state (19), 0.211 for LT state (19), and 0.114 for
death (20). FromHCC to LT state, the value of 0.016 was applied
(21), and themortality rate within 1 year after HCCdiagnosis was
derived from the nationwide HCC registry in South Korea as
0.294 (21). The probabilities associated with the LT state were
estimated using Korean Network for Organ Sharing data, and the
mortality rate applied was as 0.231 (Table 1) (22).
In cases of long-term treatment with TDF, studies have
demonstrated that renal dysfunction or low bone density disease
may occur (23,24). However, no cases using entecavir were
reported (25). After the use of TDF, the cumulative incidence of
stage 3 chronic kidney disease (CKD), which was defined as
glomerular filtration ratio ,60 mL/min/1.73 m2 and considered
to require treatment, was applied as 2% for the starting cohort
from the third year (23). In addition, the cumulative incidence of
osteopenia (22.5, bonemarrow densitymeasured by T score,
21) and osteoporosis (T score 22.5) was estimated as 2.5%,
respectively, during 4–8 years after the start of taking TDF (24).
Costs
From the health care system perspective, all estimated costs for
each health state included direct and indirect costs such as trans-
portation and caregiving. Costs for productivity loss were not in-
cluded due to the possibility of overestimation and uncertainty. All
costs were converted to the current value using an exchange rate of
1,200 KRWper 1USD for 2019. Direct costs included drugs, direct
health care, and out-of-pocket health care costs. Drug costs, spe-
cifically those associated with NUC therapy, were calculated by
multiplying theweighted average annual consumption of entecavir
and TDF by the unit prices of these drugs. The unit prices were
provided by the Health Insurance Review and Assessment Service
(HIRA) (26), a public organization in SouthKorea, and the volume
of the drugs consumed was calculated using patient sample data
from the HIRA (HIRA-NPS-2017-0052) (27,28).
The direct costs for CHB, VR, and CC states were estimated
using the data from Severance Hospital; during follow-up, pa-
tients routinely received laboratory tests every 6 months and
underwent periodic surveillance with upper abdomen ultraso-
nography and serum alpha-fetoprotein levels to screen for HCC
and cirrhotic complications every 6 months (6,29). Outpatient
costs were calculated by multiplying the unit cost of trans-
portation according to the KoreanNational Health andNutrition
Examination Survey (KNHANES) in 2017 (30) by the average
number of outpatient visits, i.e., twice a year. For estimating costs
in the UMA-CHB, CHB-VR, and CC states, hospital visits were
assumed to occur approximately twice a year for follow-up ex-
aminations; this precluded the need to calculate hospital stay and
out-of-pocket hospital costs.
Health care costs specific to the DCC, HCC, and LT states were
derived from an earlier study that used 2015 data provided by the
Asan Medical Center for analysis from the health care system per-
spective (20); these data were converted to current values before use.
In the study by Kim et al. (20), HCC-specific costs were categorized
into 3 stages: very early, early, and advanced. The costs were mul-
tiplied by the corresponding rates obtained from the Korea liver
cancer registry sample data to calculate a weighted average value for
each stage, which was then applied to the model. Costs associated
withLTwere divided into costs for the year inwhich theLToccurred
and the costs for subsequent years. The value of the former was
Table 2. Cost inputs
Health states
Annual cost (USD)
SourceMedicationa Health care Transportation Overall
UMA-CHB/CHB-VR/CC Data from HIRA (26) for drug cost; data from
Severance Hospital at 2019 for health care
costs; data from KNHNES (30) for
transportation costs
Scenario 1 861 562 17 1,440
Scenario 2 562 17 579
DCCb 8,820 Kim et al. (20)
HCCb 35,370 Kim et al. (20,21)
LTb 129,837 Kim et al. (20)
Post-LTb 13,479 Park et al. (31)
Adverse eventsa Medication Health care Transportation Overall
CKD 545 213 38 796 Data from HIRA (HIRA-NPS-2017-0052)
(27,28)
Osteopenia 158 115 24 297 Kwon et al. (32) and data from HIRA (HIRA-
NPS-2017-0052) (27,28)
Osteoporosis 425 115 24 564 Kwon et al. (32) and data from HIRA (HIRA-
NPS-2017-0052) (27,28)
All costs are 2019 values; 1 USD dollar is approximately equal to 1,200 Korean won.
CC, compensated cirrhosis; CHB-VR, chronic hepatitis B with virological response; CKD, chronic kidney disease; DCC, decompensated cirrhosis; HCC, hepatocellular
carcinoma; HIRA, health insurance review and assessment service; KNHANES, Korean National Health and Nutrition Examination Survey; LT, liver transplantation; UMA-
CHB, untreated minimally active chronic hepatitis B; USD, US dollar.
aNUC costs were limited to include in scenario 1.
bIncluding medication, health care, and transportation costs. If needed, hospitalization costs were included.





obtained from the study by Kim et al. (20) and that of the latter was
obtained from the study by Park et al. (31) (Table 2).
The costs associated with treating adverse drug reactions, such
asCKD, drug-induced osteopenia, and osteoporosis,were included
in this model and separately divided into drug costs, other health
care costs, and transportation costs. CKD costs were estimated as
costs incurred by patients in their 50s with stage 3 CKD (N18.3 of
KCD-seventh codes) diagnosis, based on data from HIRA. Health
care costs and outpatient visit costs for both drug-induced osteo-
penia and osteoporosis were calculated from patients in their 50s
with a diagnosis of drug-induced osteoporosis (M81.4 of KCD-
seventh codes), based on data from HIRA. The drug costs for
osteopenia estimated the expenditure for calcium and vitamin D;
for osteoporosis, the cost for bisphosphonates was added (32).
Utilities
In this study, the health benefits were measured as utility, life-
years gained, averted HCC, and averted deaths related to liver
diseases. For measuring utility, quality-adjusted life years
(QALYs) were used as the primary measure. We reviewed the
utility data for Koreans to apply a local utility tailored to subjects’
characteristics for each health status. A utility weight of 0.820 was
applied to patients with UMA-CHB or CHB-VR (33). As the
values of compensated and decompensated utilities of cirrhosis
optimized for South Koreans have not been reported to date, we
applied values from the work of Levy et al. (34), which was also
adopted in a recent study from South Korea (20). In the HCC
state, the values of 0.620, 0.577, and 0.440 were applied according
to the 3 stages (very early, early, and advanced) (20) and com-
bined as 0.508 using the prevalence of the nationwide HCC reg-
istry (6.6%, 41.0%, and 52.4% for each stage, respectively;
2011–2014) (21). The utility weight of the LT state was applied to
the period within a year after transplantation and subsequently
thereafter (35). To calculate disutility values, we first measured
the general utility of patients in their 50s from KNHANES data
and then subtracted the value of utility (30). The utilities of stage 3
CKD, osteopenia, and osteoporosis in Koreans were used as
QALYs of adverse event status (30,36) (Table 3).
Analysis
In this cost-effectiveness analysis, the values calculated in the
base-case analysis are expressed as an incremental cost-
effectiveness ratio (ICER) of NUC therapy vs no treatment for
patients with UMA-CHB. The ICER was calculated by dividing
incremental costs required to undergo NUC therapy vs no
treatment by incremental effectiveness, indicating health utilities
(Equation 1). Incremental heath utilities were measured as life-
years (LY) gained and QALYs gained with NUC therapy. The
number of avertedHCC cases and costs required to avert a case of
HCC after the effects of NUC therapy was calculated during the
base-case analysis in comparison with no treatment.
ICER ¼ CostNUCs  therapy 2CostNo  treatment


QALYNUCs  therapy 2QALYNo  treatment
 (1)
where ICER is incremental cost-effectiveness ratio and QALY
is quality adjusted life years.
Scenario 1 involves patients with UMA-CHB receiving NUC
therapy, and scenario 2 involves patients with UMA-CHB not
receiving NUC therapy.
Sensitivity analysis is a method used to evaluate uncertainty
arising from economic valuation parameters by measuring the
influence of fluctuations in each parameter on the value of ICER.
We performed 1-way deterministic sensitivity analyses (DSAs)
and probabilistic sensitivity analysis (PSA). One-way DSA ex-
amines fluctuations relative to variations in the range of values for
each single parameter that are clinically important or extracted
from other countries (Table 4), as well as their effects on results,
which are displayed in a tornado diagram (Figure 2). We per-
formed PSA on parameters listed in Table 4 with its specific
distribution by running 1,000 simulations. A cost-effectiveness
acceptability curve was generated to assess preference over a
range of willingness-to-pay (WTP) thresholds in South Korea.
RESULTS
Base-case analysis
From the health care system perspective, NUC therapy yielded
higher costs and greater health benefits compared with no
treatment among patients with UMA-CHB in their 50s (Table 5).
The total cost per patient over the 10-year horizon was estimated
at $15,349 for the NUC therapy group (scenario 1) and $13,148
for the no treatment group, yielding a difference of $2,201. Al-
though patients in the NUC therapy group were estimated to
spend $6,785 on NUC drug costs, $4,659 could be saved over 10
years for liver-related health care costs. The modeled simulation
over the 10-year horizon demonstrated that a patient receiving
NUC therapy gained 0.175moreQALYs (6.467 vs 6.292) than the
no treatment group. Thus, ICERs for NUC therapy compared
with those for no treatment were estimated at $12,607/QALY and
$17,644/LY gained.
If 10,000 patients with UMA-CHB received NUC therapy,
more episodes of incident HCC and liver disease-related deaths
could be prevented. In the no treatment group, 1,241 cases of new
HCC occurred out of 10,000 patients in 10 years, whereas 521
Table 3. Utility inputs
Health states Utility Source
UMA-CHB 0.820 Ock et al. (33)
CHB-VR 0.820 Ock et al. (33)
CC 0.663 Levy et al. (34)
DCC 0.391 Levy et al. (34)
HCC 0.508 Kim et al. (20,21)
LT 0.50 Aberg et al. (35)
Post-LT 0.77 Aberg et al. (35)
Death 0
Adverse events Disutility Source
CKD (stage 3) 0.119 (50.959–0.840) Data from KNHANES (30)
and Go et al. (36)
Osteopenia 0.053 (50.959–0.906) Data from KNHANES (30)
Osteoporosis 0.109 (50.959–0.850) Data from KNHANES (30)
CC, compensated cirrhosis; CHB-VR, chronic hepatitis B with virological
response; CKD, chronic kidney disease; DCC, decompensated cirrhosis; HCC,
hepatocellular carcinoma; KNHANES, Korean National Health and Nutrition
Examination Survey; LT, liver transplantation; UMA-CHB, untreated minimally
active chronic hepatitis B.
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cases developed in the NUC therapy group. NUC therapy could
avert approximately 60% (720 cases out of 10,000 patients) of new
HCC cases over 10 years. Likewise, NUC therapy could savemore
than 55% of patients’ lives (465 deaths out of 10,000 patients)
compared with no treatment (377 deaths in the NUC therapy
group vs 843 deaths in the no treatment group).
The results of additional analysis for a time horizon of 20 years
are shown in Supplemental Table 2 (see Supplementary Digital
Content, http://links.lww.com/CTG/A493). From the health care
system perspective, ICERs for NUC therapy vs no treatment over
the 20-year horizon were $2,036/QALY and $2,257/LY gained,
which are highly cost-effective compared with the results of the
10-year horizon. The analysis revealed that if 10,000 patients with
UMA-CHB continuedNUC therapy for 20 years, 1,415 new cases
of HCC and 1,257 deaths could be prevented.
One-way deterministic sensitivity analysis
One-wayDSA indicated that the annualmortality rate fromHCC
was the most influential variable for ICER change. As the mor-
tality rate for HCC changed from 8.1% to 54.5% (37), the ICER
ranged from 2$1,287 to $18,783 per QALY. If the annual mor-
tality rate from HCC decreased to less than approximately 10%,
NUC therapy yielded greater health effects and lower costs
compared with no treatment, suggesting that NUC therapy is a
cost-saving and superior option. The second most influential
variablewasNUCdrug costs.When the annualNUC therapy cost
varied from210% to110% of the base-case value ($833), ICER
was calculated from 230% to 130% of the base-case ICER
($12,607/QALY). We also considered an increase in therapy cost
by 10% in this DSA; however, given that drug costs are unlikely to
increase due to the emergence of generic drugs and the govern-
ment’s policy on drug expenditure, ICER would likely not in-
crease to 30% of the base-case ICER. All other variables including
health care costs and utility weights of each health state exhibited
smaller ICER changes (Figure 2).
Probabilistic sensitivity analysis
The results of PSA using 1,000 simulations are represented as a
cost-effective plane and cost-effectiveness acceptability curve in
Figure 3 and Figure 4. If the WTP (indicating cost-effective
threshold) was set as 1 gross domestic product (GDP) per capita
($33,000) (38), NUC therapy remained the preferred option in
83.3% of simulations for patients with UMA-CHB. Assuming
that the WTP was higher than $55,000 (1.7 times of 1 GDP per
capita), the results from all simulations indicated that NUC
therapy was an acceptable strategy.
DISCUSSION
This study assessed the cost-effectiveness of ongoing NUC ther-
apy compared with that of no treatment in patients with UMA-
CHB who were not eligible for the current criteria of NUC
therapy under the NHIS system in South Korea.We demonstrate
that NUC therapy, when provided for 10 years, was a highly cost-
effective alternative option. If 10,000 patients were under NUC
therapy, 720 incident HCC cases and 465 CHB-related deaths
could be averted compared with no treatment over 10 years.
Moreover, when the period of NUC therapy was extended to 20
years, the cost-effectiveness and clinical impact was larger.In
addition, all sensitivity analyses supported the robustness of the
cost-effectiveness of NUC therapy. Thus, this study provides





Lower value Upper value Distribution
Transition probabilities
UMA-CHB to CHB-VR at the first year at
scenario 1
0.700 0.900 Assumption Beta (0.800, 0.400)
CC to HCC 0.008 0.080 Lin et al. (37) Beta (0.043, 0.203)
DCC to LT 0.000 0.400 Kanwal et al. (14) Beta (0.211, 0.408)
DCC to death (mortality rate) 0.099 0.188 Lin et al. (37) Beta (0.114, 0.318)
HCC to LT 0.000 0.050 Kanwal et al. (14); assumption based upon
data from Asan Medical Center (20)
Beta (0.016, 0.125)
HCC to death 0.081 0.545 Lin et al. (37) Beta (0.294, 0.011)
Adverse events 0.000 0.100 Assumption —
Costs
NUC costs 210% 110% Assumption Gamma (833, 83)
Health care costs 210% 110% Assumption Gamma (189,242, 18,924)
Utilities
CC 0.570 0.700 Ock et al. (33) and Levy et al. (34) Beta (0.663, 0.015)
HCC 0.390 0.670 Levy et al. (34) Beta (0.508, 0.016)
Discounted rates 0% 7.5% Assumption —
CC, compensated cirrhosis; CHB-VR, chronic hepatitis B with virological response; DCC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver
transplantation; NUC, nucleos(t)ide analogue; UMA-CHB, untreated minimally active chronic hepatitis B.





important evidence to support scientific decision making re-
garding the expanded eligibility for NUC therapy among patients
with UMA-CHB, who do not meet the current reimbursement
criteria for NUC therapy.
Many studies have investigated the economic parameters and
outcomes of interventions for patients with CHB, primarily
comparing 2 NUCs (39,40) or diagnostic examination modalities
(20). To the best of our knowledge, this is the first study to use the
novel approach of comparing 2 scenarios with the aim of
expanding eligibility criteria for patients with UMA-CHB. Al-
though the HIRA in South Korea does not provide a fixed
threshold for assessing cost-effectiveness, it is acceptable
Table 5. Results of base-case analysis per patient over the 10-year horizon
Scenario 1 (NUC therapy) Scenario 2 (no treatment) Incremental value (scenario 1 2 scenario 2)
Total cost (USD) 15,349 13,148 2,201
Medication 6,785 0 6,785
Health care 8,489 13,148 24,659
Adverse events 76 0 76
Total effectiveness
QALY gained 6.467 6.292 0.175
LY gained 7.976 7.851 0.125
Incidence of HCC among 10,000 patients
with UMA-CHB
521 1,241 2720
No. of deaths related to liver diseases
among 10,000 patients with UMA-CHB
377 843 2465
ICER
Incremental cost per QALY (USD/QALY) 12,607
Incremental cost per LY (USD/LY) 17,644
HCC, hepatocellular carcinoma; ICER, incremental cost-effectiveness ratio; LY, life-year; NUC, nucleos(t)ide analogue; QALY, quality-adjusted life-year; UMA-CHB,
untreated minimally active chronic hepatitis B; USD, US dollar.
Figure 2. Tornadodiagramof one-way deterministic sensitivity analysis. CC, compensated cirrhosis; CHB, chronic hepatitis B; DCC, decompensated cirrhosis;
HCC, hepatocellular carcinoma; LT, liver transplantation; NUC, nucleos(t)ide analogue; UMA, untreated minimally active; VR, virological response.
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provided that new interventions have an estimated ICER of less
than 1 GDP per capita in general, and 1 GDP per capita is then
considered as the threshold of WTP (41). The GDP per capita of
South Korea was approximately $33,000 in 2018 (38). In the base-
case analysis (for a 10-year period), the estimated ICER was
$12,607/QALY and fell under the CE threshold ($33,000). This
suggests thatNUC therapywould be a highly cost-effective option
for the treatment of patients with UMA-CHB. This base-case
ICER was conservatively estimated due to the limited time ho-
rizon and perspective of the analysis. In the analysis with a
20-year horizon, the ICER of NUC therapy was $2,036/QALY,
implying that longer treatment could lead to better outcomes. As
a health care system perspective was adopted for this study, the
model did not include costs incurred from morbidity or pre-
mature death, such as lost productivity. If indirect costs were
included in the analysis, the cost-effectiveness of NUC therapy
would be expected to increase further.In addition, patients with
UMA-CHB are estimated to comprise approximately 10% of all
patients with CHB based up HIRA data (HIRA-NPS-2016-0164)
(27,28) and previous literature (9,10,42,43). Considering that the
prevalence of CHB in South Korea as of 2017 was reported to be
2.8% based on the KNHANES report (30), it is estimated that
130,000 to 140,000 patients with UMA-CHB exist. From a health
care system perspective, the average annual NUC therapy cost
over 10 years was estimated to be between 88 and 95 million US
dollars and could prevent 936 to 1,008 new cases of HCC and 604
to 651 deaths annually.
A series of analyses in the present study enabled our main
findings to be generalized for interpretation in real-life practice.
Our study had several strengths. First, we mostly adopted
Figure 4. Cost-effectiveness acceptability curve. WTP, willingness-to-pay.
Figure 3. Cost-effectiveness plane. ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.





epidemiological data, transition probabilities, cost, and utilities
from the most recent real-world evidence in South Korea, which
more practically reflects local clinical environments such as the
patterns of antiviral prescription (e.g., entecavir vs TDF), HCC
surveillance strategy consisting of alpha-fetoprotein and ultra-
sonography, distribution of tumor stages among newly developed
HCC cases, and recent experiences of liver transplantation. In
particular, we incorporated the potential hazards from long-term
NUC therapy (e.g., CKD and osteopenia/osteoporosis by TDF
use) into the cost-effective analysis. Furthermore, representative
big data from South Korea (e.g., data from the HIRA) were an-
alyzed to directly calculate health care costs. Second, we applied
the transition probabilities of the first year and subsequent pe-
riods when shifting the health status from CHB to VR. This ap-
proach enabled more accurate reflection of the clinical course of
patients undergoing NUC therapy, given that the proportion of
VRs by NUC therapy increases steeply within the first year of
starting NUCs.In addition, because the results of sensitivity
analyses, including one-way DSA and PSA, exhibited small ICER
changes and a high probability of acceptance, the high cost-
effectiveness of NUC therapy was proven with robust estimation
of ICER. Finally, our results are applicable for improving both
individual health and balancing medical expenses in many
countries (e.g., Japan, Taiwan, and others in the East Asia), which
have a similar epidemiology of chronic HBV infection and re-
imbursement program to those of South Korea (7,44,45).
Our study has several limitations. Theremay have been under-
and/or overestimation of health care costs. For example, the
hospitalization and out-of-pocket health care costs in the health
states of CHB, VR, and CC were excluded; therefore, the actual
costs may have been underestimated. Conversely, overestimation
of costs may have occurred given that costs were based on data
from academic tertiary referral hospitals and patients visiting
such institutions are more likely to have relatively severe disease
conditions. However, out-of-pocket payment for surcharges by
physicians in South Korea was abolished in 2018, and upper
abdomen ultrasonography started to be reimbursed. Therefore,
the gap between expected and actual costs was substantially
narrowed. To overcome these shortcomings, we simultaneously
evaluated the overall costs from patient sample data from the
HIRA (HIRA-NPS-2016-0164) (27,28), revealing that there were
only minimal differences in the costs of UMA-CHB, CHB-VR,
and CC states ($579 calculated from academic tertiary referral
hospitals such as Severance Hospital vs $ 570 from the HIRA
patient sample data). Regarding health states such as DCC, HCC,
and LT, our data may be regarded as reasonable as these patients
are often hospitalized due to severe medical conditions and typ-
ically managed in large hospitals. The sensitivity analysis, which
was conducted based on a previous study that assessed the ro-
bustness of study results relative to changes in costs using health
insurance claim data, also confirmed the robustness of the cost-
effectiveness reported in this study.
In conclusion, long-term NUC therapy is a highly cost-
effective intervention for patients with UMA-CHB. Inclusion of
long-term NUC therapy in the reimbursement program by the
NHIS may improve individual health and reduce the overall so-
cioeconomic burden of this disease.
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Study Highlights
WHAT IS KNOWN
3 AVT for CHB can prevent liver disease progression. However,
because of its stringent reimbursement criteria, significant
numbers of patients with UMA-CHB exist, although they are
still subject to disease progression.
WHAT IS NEW HERE
3 The simulation of AVT vs no treatment predicted $2,201
incremental costs and 0.175 incremental QALYs per patient
for 10 years, with an incremental cost-effectiveness ratio of
$12,607/QALY, suggesting cost-effectiveness of AVT.
TRANSLATIONAL IMPACT
3 Long-term AVT for patients with UMA-CHB may contribute
positively toward individual clinical benefit and national
health care budget.
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